$24.53
3.20% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US61023L1089
Symbol
MNPR
Sector
Industry

Monopar Therapeutics Inc Stock price

$24.53
+3.83 18.50% 1M
+20.82 560.74% 6M
+22.83 1,342.09% YTD
+22.63 1,193.09% 1Y
+8.68 54.76% 3Y
-74.42 75.21% 5Y
-107.97 81.49% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.81 3.20%
ISIN
US61023L1089
Symbol
MNPR
Sector
Industry

Key metrics

Market capitalization $149.06m
Enterprise Value $143.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 17.48
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-7.00m
Free Cash Flow (TTM) Free Cash Flow $-5.95m
Cash position $6.02m
EPS (TTM) EPS $-1.98
Short interest 10.22%
Show more

Is Monopar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Monopar Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Monopar Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Monopar Therapeutics Inc forecast:

Buy
100%

Financial data from Monopar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.88 2.88
9% 9%
-
- Research and Development Expense 4.12 4.12
38% 38%
-
-7 -7
29% 29%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -7 -7
29% 29%
-
Net Profit -6.47 -6.47
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Monopar Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monopar Therapeutics Inc Stock News

Positive
Seeking Alpha
5 days ago
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor patients is likely to respond to MNPR-101-Lu in a phase 1 study. The global solid tumor cancer treatment market size is projected to hit around $532.42 billion by 2032; uPAR expression is high in a v...
Neutral
GlobeNewsWire
9 days ago
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addi...
Neutral
GlobeNewsWire
23 days ago
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase ...
More Monopar Therapeutics Inc News

Company Profile

Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Head office United States
CEO Chandler Robinson
Employees 10
Founded 2014
Website www.monopartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today